Abstract
Cancer stem cells (CSCs) in a variety of tumor types have intrinsically greater resistance to ionizing radiation (IR) than the remaining cancer cells. Since surviving CSCs have the capacity to regenerate tumor deposits, CSC radioresistance represents an important clinical problem. Here we discuss mechanisms that CSCs employ to resist IR and therapeutic strategies that are currently being used in the clinic or are in various stages of development for overcoming these. While much ongoing work shows promise for increasing the efficacy of IR through rational targeting of CSCs, well-designed clinical trials testing such strategies will be required to bring these approaches into the clinic.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Armanios M, Greider CW (2005) Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 70:205–208
Babashah S (ed) (2014) MicroRNAs: key regulators of oncogenesis. Springer International Publishing Switzerland, Cham
Babashah S, Soleimani M (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 47(8):1127–1137
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra224
Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I (2005) Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid Redox Signal 7(1–2):32–41
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH et al (2010) In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28(28):4324–4332
Brown JM, Diehn M, Loo BW Jr (2010) Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 78(2):323–327
Calin GA, Croce CM (2006a) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866
Calin GA, Croce CM (2006b) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66(15):7390–7394
Cao C, Mu Y, Hallahan DE, Lu B (2004) XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23(42):7047–7052
Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79(4):1188–1195
Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699–713
Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F et al (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71(4):1374–1384
Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O’Connell RM et al (2011) MicroRNA-125b potentiates macrophage activation. J Immunol 187(10):5062–5068
Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD et al (2012) Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA 109(11):4233–4238
Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121(1):396–409
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783
Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4(9):721–726
Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26(17):2839–2845
Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N et al (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28(1):5–16
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159
Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC (2013) An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1(6):365–372
Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A et al (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5(10):1164–1170
Hiniker SM, Chen DS, Knox SJ (2012a) Abscopal effect in a patient with melanoma. N Engl J Med 366(21):2035; author reply 2035–2036
Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA et al (2012b) A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5(6):404–407
Hiyama E, Hiyama K (2007) Telomere and telomerase in stem cells. Br J Cancer 96(7):1020–1024
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19(3):387–400
Iwata H, Sato K, Tatewaki K, Yokota N, Inoue M, Baba Y et al (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro Oncol 13(8):916–922
Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R et al (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271–285
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015
Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ et al (2012) In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood 119(2):355–363
Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M et al (2013) Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5(167):167ra164
Kobayashi CI, Suda T (2012) Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol 227(2):421–430
LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG (2008) IAP-targeted therapies for cancer. Oncogene 27(48):6252–6275
Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R et al (2010) Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 70(1):338–346
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513
Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z et al (2009) A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 37(3), e24
Moding EJ, Lee CL, Castle KD, Oh P, Mao L, Zha S et al (2014) Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. J Clin Invest 124(8):3325–3338
Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE et al (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011:941876
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548–554
O’Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205(3):585–594
O’Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D (2010a) MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci USA 107(32):14235–14240
O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D (2010b) Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 10(2):111–122
Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF et al (2007) Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 96(8):1223–1233
Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777–1785
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931
Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3):172–183
Rubio MA, Davalos AR, Campisi J (2004) Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress. Exp Cell Res 298(1):17–27
Ruggieri R, Naccarato S, Nahum AE (2010) Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncol 49(8):1304–1314
Senan S, Palma DA, Lagerwaard FJ (2011) Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies. J Thorac Dis 3(3):189–196
Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33(5):787–791
Sheridan C (2014) Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol 32(4):297–299
Shimura T, Kakuda S, Ochiai Y, Kuwahara Y, Takai Y, Fukumoto M (2011) Targeting the AKT/GSK3beta/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy. Int J Radiat Oncol Biol Phys 80(2):540–548
Shimura T, Fukumoto M, Kunugita N (2013) The role of cyclin D1 in response to long-term exposure to ionizing radiation. Cell Cycle 12(17):2738–2743
Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W et al (2009) Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 4(7), e6377
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ et al (2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24(7):1813–1821
So AY, Sookram R, Chaudhuri AA, Minisandram A, Cheng D, Xie C et al (2014) Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood 124(9):1502–1512
Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA et al (2014) CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74(23):6771–6783
Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103(33):12481–12486
Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM et al (2013) A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a children’s oncology group phase I consortium study (ADVL1112). Clin Cancer Res 19(23):6578–6584
Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM et al (2012) Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72(13):3163–3174
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109(17):6662–6667
Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 104(2):618–623
Wu X, Smavadati S, Nordfjall K, Karlsson K, Qvarnstrom F, Simonsson M et al (2012) Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochim Biophys Acta 1823(12):2130–2135
Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J et al (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71(2):484–490
Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349
Zhao JL, Rao DS, Boldin MP, Taganov KD, O’Connell RM, Baltimore D (2011) NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 108(22):9184–9189
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chaudhuri, A.A., Binkley, M.S., Diehn, M. (2015). Cancer Stem Cells and Tumor Radioresistance. In: Babashah, S. (eds) Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-21030-8_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-21030-8_18
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21029-2
Online ISBN: 978-3-319-21030-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)